RoenRx: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of RoenRx’s website, https://roenrx.com, FDA Establishment Identifier (FEI) 3044022969, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products.

1. 1

   “The compounded semaglutide products displayed on your website identify “RoenRx” on the pictured label, suggesting RoenRx is the compounder of those drugs when in fact it is not.”

2. 2

   ““RoenRx also offers semaglutide, the active ingredient in Wegovy® and Ozempic®….””

3. 3

   ““Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price.””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

roenrx.com returned a live storefront when we checked in August 2026, covering weight loss, hair, sexual health, birth control, mental health and skincare. We did not review every page on the site.

The most useful thing on this page is something you can check yourself in about a minute: open this letter and the AM RX letter side by side, both dated June 2026, and read the quoted claims. One sentence is identical, down to the odd repetition of "affordable" twice in twelve words. Another differs only by the company name. These are two separately named businesses that were writing the same product page. Nothing in either letter says who wrote it first or whether the two are connected, and we are not asserting that they are — but it does undercut the idea that comparing several telehealth brands means comparing several independent offers. Some of these storefronts are assembled from shared parts. When two listings quote you similar prices in similar words, the sensible next question is which pharmacy actually fills each one, which is precisely what FDA asked both companies to disclose.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence RoenRx failed to respond.